New 30-year study links inflammation and cholesterol to higher stroke risk in women. Keep reading to find out more.

San Diego-based inflammatory diseases specialist Ventyx Biosciences announced positive results from its Phase II study of ...

Ventyx Biosciences Inc. (NASDAQ: VTYX) jumped 86.53% to $7.20 in after-hours trading on Wednesday after the company reported ...

Ventyx Biosciences shares more than doubled in premarket trading Thursday after the clinical-stage biopharmaceutical company reported positive results from a mid-stage study of its VTX3232 drug ...

The San Diego-based biotech has been evaluating the oral NLRP3 inhibitor, dubbed VTX3232, in a phase 2 study of 175 patients ...

Ventyx Biosciences, Inc. surged after strong Phase 2 results for VTX3232 in obesity. Click for key insights and what VTYX ...

VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the ...

Ventyx Biosciences (VTYX) stock soar as the company announces data from a Phase 2 trial showing the potential of its cardiovascular drug VTX3232. Read more here.

New research reveals cocoa extract as a natural ally against age-related inflammation. Flavanols in cocoa help reduce ...

The drug’s effects on cardiovascular and inflammation markers outshined its failure to spur weight loss, analysts wrote.

Investing.com -- Ventyx Biosciences (NASDAQ:VTYX) stock soared 45% in after-hours trading Wednesday following the company’s announcement of positive topline results from its Phase 2 study of VTX3232 ...

A new study from Florida Atlantic University’s Charles E. Schmidt College of Medicine found that people who eat the most UPFs ...